{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:13:13Z","timestamp":1793747593143,"version":"4.6.1"},"reference-count":185,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Corneal neovascularization (CoNV) is a sight-threatening condition affecting an estimated 1.4 million people per year, and the incidence is expected to rise. It is a complication of corneal pathological diseases such as infective keratitis, chemical burn, corneal limbal stem cell deficiency, mechanical trauma, and immunological rejection after keratoplasties. CoNV occurs due to a disequilibrium in proangiogenic and antiangiogenic mediators, involving a complex system of molecular interactions. Treatment of CoNV is challenging, and no therapy thus far has been curative. Anti-inflammatory agents such as corticosteroids are the mainstay of treatment due to their accessibility and well-studied safety profile. However, they have limited effectiveness and are unable to regress more mature neovascularization. With the advent of advanced imaging modalities and an expanding understanding of its pathogenesis, contemporary treatments targeting a wide array of molecular mechanisms and surgical options are gaining traction. This review aims to summarize evidence regarding conventional and emerging therapeutic options for CoNV.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3043_23","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T04:00:53Z","timestamp":1713585653000},"page":"S354-S371","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Management of corneal neovascularization: Current and emerging therapeutic approaches"],"prefix":"10.4103","volume":"72","author":[{"given":"Duoduo","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Chan","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanche Xiao Hong","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn Ka-Ann","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Meihua","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Manotosh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris Hong Long","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"School of Optometry and Vision Science, University of New South Wales, Sydney, Australia"},{"name":"Singapore Eye Research Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: An epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijo.IJO_646_17","article-title":"Anatomy of cornea and ocular surface","volume":"66","author":"Sridhar","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2013.01.018","article-title":"Human corneal anatomy redefined: A novel pre- Descemet\u2019s layer (Dua\u2019s layer)","volume":"120","author":"Dua","year":"2013","journal-title":"Ophthalmology"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis","volume":"88","author":"Qazi","year":"2009","journal-title":"J Genet"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: Beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/jcb.30344","article-title":"Molecular mechanism of VEGF and its role in pathological angiogenesis","volume":"123","author":"Ahmad","year":"2022","journal-title":"J Cell Biochem"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04480","article-title":"Lymphangiogenesis in development and human disease","volume":"438","author":"Alitalo","year":"2005","journal-title":"Nature"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1167\/iovs.16-19420","article-title":"Proangiogenic interactions of vascular endothelial MMP14 with VEGF receptor 1 in VEGFA-mediated corneal angiogenesis","volume":"57","author":"Han","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12885-017-3418-y","article-title":"Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma","volume":"17","author":"Webb","year":"2017","journal-title":"BMC Cancer"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"8549","DOI":"10.1167\/iovs.11-7956","article-title":"Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing","volume":"52","author":"Ebihara","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1167\/iovs.08-2732","article-title":"Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist","volume":"50","author":"Lu","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40662-017-0094-6","article-title":"Therapeutic approaches for corneal neovascularization","volume":"4","author":"Feizi","year":"2017","journal-title":"Eye Vis (Lond)"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1083\/jcb.152.6.1247","article-title":"Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation","volume":"152","author":"Troyanovsky","year":"2001","journal-title":"J Cell Biol"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5966\/sctm.2011-0037","article-title":"Concise review: Limbal stem cell deficiency, dysfunction, and distress","volume":"1","author":"Ahmad","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08820530902801478","article-title":"Limbal stem cell deficiency and corneal neovascularization","volume":"24","author":"Lim","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.exer.2009.09.023","article-title":"In sickness and in health: Corneal epithelial stem cell biology, pathology and therapy","volume":"90","author":"Notara","year":"2010","journal-title":"Exp Eye Res"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.preteyeres.2013.01.001","article-title":"Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases","volume":"34","author":"Bock","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-2999(97)01464-7","article-title":"Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells","volume":"341","author":"Nauck","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s004170100313","article-title":"Impact of short- term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty","volume":"239","author":"Cursiefen","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.22336\/rjo.2019.4","article-title":"Corneal neovascularization: Updates on pathophysiology, investigations & management","volume":"63","author":"Sharif","year":"2019","journal-title":"Rom J Ophthalmol"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":"Inhibition of corneal neovascularization after alkali burn: Comparison of di\ufb00erent doses of bevacizumab in monotherapy or associated with dexamethasone","volume":"38","author":"Ho\ufb00art","year":"2010","journal-title":"Clin Exp Ophthalmol"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel","year":"2018","journal-title":"Ocul Surf"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side e\ufb00ects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jss.2008.03.016","article-title":"Cyclosporine inhibition of angiogenesis involves the transcription factor HESR1","volume":"149","author":"Shah","year":"2008","journal-title":"J Surg Res"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00417-013-2467-4","article-title":"Inhibitory e\ufb00ects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits","volume":"251","author":"Bucak","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ophtha.2014.03.016","article-title":"High-dose subconjunctival cyclosporine a implants do not a\ufb00ect corneal neovascularization after high-risk keratoplasty","volume":"121","author":"Bock","year":"2014","journal-title":"Ophthalmology"},{"key":"R28-20260504","first-page":"189","article-title":"Cyclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high- performance liquid chromatography-electrospray mass spectrometry","volume":"5","author":"Althaus","year":"1996","journal-title":"Ger J Ophthalmol"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive e\ufb00ect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/02713683.2010.516620","article-title":"The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization","volume":"36","author":"Turgut","year":"2011","journal-title":"Curr Eye Res"},{"key":"R31-20260504","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.2147\/DDDT.S175297","article-title":"The long-term e\ufb00ect of tacrolimus on alkali burn-induced corneal neovascularization and inflammation surpasses that of anti-vascular endothelial growth factor","volume":"12","author":"Chen","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R32-20260504","doi-asserted-by":"crossref","first-page":"791954","DOI":"10.3389\/fbioe.2021.791954","article-title":"Inhibition of neovascularization and inflammation in a mouse model of corneal alkali burns using cationic liposomal tacrolimus","volume":"9","author":"Lin","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"R33-20260504","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41433-019-0717-3","article-title":"Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: A randomized clinical trial study","volume":"34","author":"Zhai","year":"2020","journal-title":"Eye (Lond)"},{"key":"R34-20260504","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcjo.2012.12.003","article-title":"E\ufb00ects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization","volume":"48","author":"Ozdemir","year":"2013","journal-title":"Can J Ophthalmol"},{"key":"R35-20260504","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1097\/ICO.0000000000000220","article-title":"E\ufb00ects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits","volume":"33","author":"Yoo","year":"2014","journal-title":"Cornea"},{"key":"R36-20260504","first-page":"220","article-title":"Inhibitory e\ufb00ects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization","volume":"7","author":"Onder","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"R37-20260504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1735-1995.200266","article-title":"Comparison of di\ufb00erent doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats","volume":"22","author":"Hashemian","year":"2017","journal-title":"J Res Med Sci"},{"key":"R38-20260504","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/02713683.2011.601840","article-title":"The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model","volume":"36","author":"Sener","year":"2011","journal-title":"Curr Eye Res"},{"key":"R39-20260504","first-page":"136","article-title":"Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model","volume":"6","author":"Akar","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"R40-20260504","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/ICO.0000000000000507","article-title":"Inhibitory effect of topical aflibercept on corneal neovascularization in rabbits","volume":"34","author":"Park","year":"2015","journal-title":"Cornea"},{"key":"R41-20260504","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1038\/s41433-020-01347-3","article-title":"Intrastromal versus subconjunctival anti- VEGF agents for treatment of corneal neovascularization: A rabbit study","volume":"35","author":"Ucgul","year":"2021","journal-title":"Eye (Lond)"},{"key":"R42-20260504","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-20260504","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R44-20260504","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajo.2012.06.007","article-title":"Short-term topical bevacizumab in the treatment of stable corneal neovascularization","volume":"154","author":"Cheng","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R45-20260504","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The e\ufb00ect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R46-20260504","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and e\ufb03cacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R47-20260504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R48-20260504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ICO.0b013e3182542613","article-title":"Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: A meta-analysis","volume":"32","author":"Papathanassiou","year":"2013","journal-title":"Cornea"},{"key":"R49-20260504","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"R50-20260504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: Ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul Surf"},{"key":"R51-20260504","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5301\/ejo.5000391","article-title":"The e\ufb00ect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: Study on an animal model","volume":"24","author":"Liarakos","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"R52-20260504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3341\/kjo.2013.27.4.235","article-title":"The e\ufb00ect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: A preliminary study","volume":"27","author":"Kim","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"R53-20260504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/jop.2020.0010","article-title":"E\ufb00ect of topical instillation of pegaptanib sodium upon inflammatory corneal neovascularization in rabbits","volume":"37","author":"Andrade","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"R54-20260504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40942-016-0026-y","article-title":"Fusion proteins for treatment of retinal diseases: Aflibercept, ziv-aflibercept, and conbercept","volume":"2","author":"de Oliveira Dias","year":"2016","journal-title":"Int J Retina Vitreous"},{"key":"R55-20260504","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.2147\/DDDT.S177192","article-title":"The e\ufb03cacy and safety of aflibercept and conbercept in diabetic macular edema","volume":"12","author":"Cai","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R56-20260504","doi-asserted-by":"crossref","first-page":"9603271221084674","DOI":"10.1177\/09603271221084674","article-title":"The e\ufb00ects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization","volume":"41","author":"Eski","year":"2022","journal-title":"Hum Exp Toxicol"},{"key":"R57-20260504","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.exer.2016.03.021","article-title":"E\ufb03cacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model","volume":"146","author":"Sella","year":"2016","journal-title":"Exp Eye Res"},{"key":"R58-20260504","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ICL.0000000000000709","article-title":"Subconjunctival aflibercept for the treatment of formed corneal neovascularization","volume":"47","author":"Sella","year":"2021","journal-title":"Eye Contact Lens"},{"key":"R59-20260504","doi-asserted-by":"crossref","first-page":"6084270","DOI":"10.1155\/2016\/6084270","article-title":"Intrastromal injection of bevacizumab in the management of corneal neovascularization: About 25 eyes","volume":"2016","author":"Sarah","year":"2016","journal-title":"J Ophthalmol"},{"key":"R60-20260504","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","article-title":"Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization","volume":"30","author":"Yeung","year":"2011","journal-title":"Cornea"},{"key":"R61-20260504","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1167\/iovs.14-15257","article-title":"Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization","volume":"55","author":"Kim","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R62-20260504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00417-019-04519-4","article-title":"Intrastromal bevacizumab in the management of corneal neovascularization: A retrospective review","volume":"258","author":"Gupta","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R63-20260504","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/wound.2013.0496","article-title":"Anti-angiogenic drugs: Involvement in cutaneous side e\ufb00ects and wound-healing complication","volume":"3","author":"Bodnar","year":"2014","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"R64-20260504","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":"Safety profile of topical VEGF neutralization at the cornea","volume":"50","author":"Bock","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R65-20260504","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"R66-20260504","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model","volume":"150","author":"P\u00e9rez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R67-20260504","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic e\ufb00ect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R68-20260504","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/ICO.0b013e31823f8d71","article-title":"E\ufb00ects of subconjunctival bevacizumab on corneal neovascularization: Results of a prospective study","volume":"31","author":"Benayoun","year":"2012","journal-title":"Cornea"},{"key":"R69-20260504","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1097\/ICO.0b013e31825ec407","article-title":"Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab","volume":"32","author":"Chu","year":"2013","journal-title":"Cornea"},{"key":"R70-20260504","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1159\/000510114","article-title":"Resolution of refractory corneal neovascularization with subconjunctival bevacizumab","volume":"11","author":"Britton","year":"2020","journal-title":"Case Rep Ophthalmol"},{"key":"R71-20260504","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2147\/OPTH.S65298","article-title":"Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab","volume":"8","author":"Cavallini","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R72-20260504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1752-1947-7-199","article-title":"Treatment of corneal neovascularization in ocular chemical injury with an o\ufb00-label use of subconjunctival bevacizumab: A case report","volume":"7","author":"Iannetti","year":"2013","journal-title":"J Med Case Rep"},{"key":"R73-20260504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3928\/1081-597X-19950101-12","article-title":"Comparison of yellow dye, continuous wave Nd:YAG, and argon green laser on experimentally induced corneal neovascularization","volume":"11","author":"Krasnick","year":"1995","journal-title":"J Refract Surg"},{"key":"R74-20260504","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archopht.1988.01060130742036","article-title":"Photothrombosis of corneal neovascularization by intravenous rose bengal and argon laser irradiation","volume":"106","author":"Huang","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"R75-20260504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(93)31706-9","article-title":"Laser photocoagulation of experimental corneal stromal vascularization. E\ufb03cacy and histopathology","volume":"100","author":"Nirankari","year":"1993","journal-title":"Ophthalmology"},{"key":"R76-20260504","first-page":"235","article-title":"Frequency doubled Nd:YAG (532 nm) laser photocoagulation in corneal vascularisation: E\ufb03cacy and time sequenced changes","volume":"49","author":"Sharma","year":"2001","journal-title":"Indian J Ophthalmol"},{"key":"R77-20260504","first-page":"Nc01","article-title":"Role of frequency doubled Nd: Yag Laser in treatment of corneal neovascularisation","volume":"10","author":"Kumar","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R78-20260504","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1167\/iovs.17-22904","article-title":"Photodynamic therapy leads to time-dependent regression of pathologic corneal (Lymph) angiogenesis and promotes high-risk corneal allograft survival","volume":"58","author":"Hou","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R79-20260504","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bjophthalmol-2013-303887","article-title":"Regression of mature lymphatic vessels in the cornea by photodynamic therapy","volume":"98","author":"Bucher","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R80-20260504","first-page":"2148","article-title":"Fine needle diathermy occlusion of corneal vessels","volume":"41","author":"Pillai","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R81-20260504","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bjophthalmol-2014-304891","article-title":"Fine needle diathermy occlusion of corneal vessels","volume":"98","author":"Faraj","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R82-20260504","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1038\/s41598-020-60705-z","article-title":"Supplemental Anti Vegf A-therapy prevents rebound neovascularisation after fine needle diathermy treatment to regress pathological corneal (LYMPH) angiogenesis","volume":"10","author":"Le","year":"2020","journal-title":"Sci Rep"},{"key":"R83-20260504","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1097\/TXD.0000000000000894","article-title":"Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: A pilot study","volume":"5","author":"Hos","year":"2019","journal-title":"Transplant Direct"},{"key":"R84-20260504","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/ICO.0000000000000419","article-title":"Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children","volume":"34","author":"Elbaz","year":"2015","journal-title":"Cornea"},{"key":"R85-20260504","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1038\/s41598-018-24037-3","article-title":"Fine needle-diathermy regresses pathological corneal (Lymph) angiogenesis and promotes high-risk corneal transplant survival","volume":"8","author":"Le","year":"2018","journal-title":"Sci Rep"},{"key":"R86-20260504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.87.1.101","article-title":"Pericyte recruitment in human corneal angiogenesis: An ultrastructural study with clinicopathological correlation","volume":"87","author":"Cursiefen","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R87-20260504","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2015.02.012","article-title":"Corneal angiography for guiding and evaluating fine-needle diathermy treatment of corneal neovascularization","volume":"122","author":"Spiteri","year":"2015","journal-title":"Ophthalmology"},{"key":"R88-20260504","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.ophtha.2014.04.025","article-title":"Medically reversible limbal stem cell disease: Clinical features and management strategies","volume":"121","author":"Kim","year":"2014","journal-title":"Ophthalmology"},{"key":"R89-20260504","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamaophthalmol.2020.1120","article-title":"Outcomes of limbal stem cell transplant: A meta-analysis","volume":"138","author":"Le","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R90-20260504","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/bjophthalmol-2011-301164","article-title":"Simple limbal epithelial transplantation (SLET): A novel surgical technique for the treatment of unilateral limbal stem cell deficiency","volume":"96","author":"Sangwan","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R91-20260504","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/sctm.19-0203","article-title":"Simple limbal epithelial transplantation: Current status and future perspectives","volume":"9","author":"Jackson","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"R92-20260504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.thromres.2004.09.001","article-title":"In vitro e\ufb00ect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells","volume":"115","author":"Seki","year":"2005","journal-title":"Thromb Res"},{"key":"R93-20260504","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s10792-022-02240-6","article-title":"Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization","volume":"42","author":"Mimouni","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R94-20260504","first-page":"9","article-title":"Outcomes of mitomycin C intravascular chemoembolization (MICE) in refractory corneal neovascularization after failed keratoplasty","volume":"29","author":"Addeen","year":"2023","journal-title":"Digit J Ophthalmol"},{"key":"R95-20260504","doi-asserted-by":"crossref","first-page":"686630","DOI":"10.3389\/fphar.2021.686630","article-title":"Corneal cross-linking: The evolution of treatment for corneal diseases","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol"},{"key":"R96-20260504","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1167\/iovs.17-23036","article-title":"Corneal collagen cross-linking with Riboflavin and UVA regulates hemangiogenesis and lymphangiogenesis in rats","volume":"59","author":"Zhu","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R97-20260504","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejphar.2006.07.045","article-title":"Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in di\ufb00erent experimental models","volume":"547","author":"Bertollo","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R98-20260504","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1167\/iovs.15-18343","article-title":"Short-term ultraviolet A irradiation leads to dysfunction of the limbal niche cells and an antilymphangiogenic and anti- inflammatory micromilieu","volume":"57","author":"Notara","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R99-20260504","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/ajt.14874","article-title":"UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival","volume":"18","author":"Hou","year":"2018","journal-title":"Am J Transplant"},{"key":"R100-20260504","doi-asserted-by":"crossref","first-page":"7325483","DOI":"10.1155\/2018\/7325483","article-title":"E\ufb00ect of collagen cross-linking on alkali burn-induced corneal neovascularization in rabbits","volume":"2018","author":"Xu","year":"2018","journal-title":"J Ophthalmol"},{"key":"R101-20260504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/02713683.2021.1971722","article-title":"Comparative analysis of matrix-regenerating agent and corneal cross-linking in an experimental alkali burn rabbit model","volume":"47","author":"Kesim","year":"2022","journal-title":"Curr Eye Res"},{"key":"R102-20260504","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/ICO.0000000000001276","article-title":"Comparison of collagen cross-linking and amniotic membrane transplantation in an experimental alkali burn rabbit model","volume":"36","author":"Subasi","year":"2017","journal-title":"Cornea"},{"key":"R103-20260504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5935\/0004-2749.20140078","article-title":"Induction of corneal collagen cross-linking in experimental corneal alkali burns in rabbits","volume":"77","author":"Colombo-Barboza","year":"2014","journal-title":"Arq Bras Oftalmol"},{"key":"R104-20260504","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ICO.0000000000002406","article-title":"Corneal crosslinking to regress pathologic corneal neovascularization before high-risk keratoplasty","volume":"40","author":"Schaub","year":"2021","journal-title":"Cornea"},{"key":"R105-20260504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu Rev Med"},{"key":"R106-20260504","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1566523221666210423084233","article-title":"Gene therapy in the anterior eye segment","volume":"22","author":"Amador","year":"2022","journal-title":"Curr Gene Ther"},{"key":"R107-20260504","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.gt.3301695","article-title":"Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy","volume":"9","author":"Lai","year":"2002","journal-title":"Gene Ther"},{"key":"R108-20260504","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/ICO.0b013e318206c893","article-title":"Gene transfer using micellar nanovectors inhibits corneal neovascularization in vivo","volume":"30","author":"Iriyama","year":"2011","journal-title":"Cornea"},{"key":"R109-20260504","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bbrc.2007.07.114","article-title":"Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression","volume":"361","author":"Yu","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R110-20260504","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/gt.2009.50","article-title":"Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model","volume":"16","author":"Yoon","year":"2009","journal-title":"Gene Ther"},{"key":"R111-20260504","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1006\/exer.2002.2075","article-title":"Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA","volume":"75","author":"Lai","year":"2002","journal-title":"Exp Eye Res"},{"key":"R112-20260504","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1167\/iovs.11-9139","article-title":"Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization","volume":"53","author":"Qazi","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R113-20260504","first-page":"2344","article-title":"Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis","volume":"13","author":"Cheng","year":"2007","journal-title":"Mol Vis"},{"key":"R114-20260504","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1089\/hum.2013.079","article-title":"Suppression of neovascularization of donor corneas by transduction with equine infectious anemia virus-based lentiviral vectors expressing endostatin and angiostatin","volume":"25","author":"Parker","year":"2014","journal-title":"Hum Gene Ther"},{"key":"R115-20260504","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/nano9040631","article-title":"MMP-9 downregulation with lipid nanoparticles for inhibiting corneal neovascularization by gene silencing","volume":"9","author":"Torrecilla","year":"2019","journal-title":"Nanomaterials (Basel)"},{"key":"R116-20260504","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exer.2019.03.006","article-title":"Cholesterol modification of SDF-1-specific siRNA enables therapeutic targeting of angiogenesis through Akt pathway inhibition","volume":"184","author":"Chen","year":"2019","journal-title":"Exp Eye Res"},{"key":"R117-20260504","first-page":"100183","article-title":"E\ufb03cient ocular delivery of siRNA via pH-sensitive vehicles for corneal neovascularization inhibition","volume":"5","author":"Cao","year":"2023","journal-title":"Int J Pharm X"},{"key":"R118-20260504","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","article-title":"Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study","volume":"121","author":"Cursiefen","year":"2014","journal-title":"Ophthalmology"},{"key":"R119-20260504","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.2147\/IJN.S375570","article-title":"An update on novel ocular nanosystems with possible benefits in the treatment of corneal neovascularization","volume":"17","author":"Zhang","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"R120-20260504","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archophthalmol.2011.42","article-title":"Suppression of Inflammatory corneal lymphangiogenesis by application of topical corticosteroids","volume":"129","author":"Hos","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R121-20260504","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/archopht.1980.01020031092017","article-title":"Use of flurbiprofen to inhibit corneal neovascularization","volume":"98","author":"Cooper","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"R122-20260504","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1167\/iovs.07-1527","article-title":"Di\ufb00erential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs","volume":"49","author":"Pakneshan","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R123-20260504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5935\/0004-2749.20220004","article-title":"Comparison of the inhibitory e\ufb00ect of topical cyclosporine A 0.1% and topical anti-VEGF application in an experimental model of corneal neovascularization","volume":"85","author":"Ulusoy","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"R124-20260504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/IAE.0b013e3181e46ad8","article-title":"The e\ufb00ect of methotrexate on corneal neovascularization in rabbits","volume":"30","author":"Byun","year":"2011","journal-title":"Cornea"},{"key":"R125-20260504","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","article-title":"Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor","volume":"236","author":"Kruse","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R126-20260504","first-page":"476","article-title":"Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis","volume":"52","author":"Abbas","year":"2002","journal-title":"J Pak Med Assoc"},{"key":"R127-20260504","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ICO.0b013e318292a79d","article-title":"The inhibitory e\ufb00ect of thalidomide analogue on corneal neovascularization in rabbits","volume":"32","author":"Lee","year":"2013","journal-title":"Cornea"},{"key":"R128-20260504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00003226-199807000-00011","article-title":"Topical modulation of interleukin-1 activity in corneal neovascularization","volume":"17","author":"Dana","year":"1998","journal-title":"Cornea"},{"key":"R129-20260504","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s10792-023-02695-1","article-title":"E\ufb00ect of adalimumab on experimental corneal neovascularization model","volume":"43","author":"\u00d6zkaya","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R130-20260504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1167\/iovs.12-11032","article-title":"Safety and e\ufb03cacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization","volume":"54","author":"Amparo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R131-20260504","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7150\/thno.65098","article-title":"Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"R132-20260504","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":"E\ufb00ects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R133-20260504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: A pilot randomised placebo-controlled double- masked trial","volume":"97","author":"Petsoglou","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R134-20260504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICO.0000000000000007","article-title":"Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits","volume":"33","author":"Kim","year":"2014","journal-title":"Cornea"},{"key":"R135-20260504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/112067211002000106","article-title":"VEGF Trap(R1R2) suppresses experimental corneal angiogenesis","volume":"20","author":"Oliveira","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"R136-20260504","doi-asserted-by":"crossref","first-page":"09603271221084674","DOI":"10.1177\/09603271221084674","article-title":"The e\ufb00ects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization","volume":"41","author":"Eski","year":"2022","journal-title":"Hum Exp Toxicol"},{"key":"R137-20260504","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.2147\/OPTH.S260302","article-title":"E\ufb00ects of VEGF inhibitor conbercept on corneal neovascularization following penetrating keratoplasty in rabbit model","volume":"14","author":"Liu","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R138-20260504","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/08820538.2023.2201652","article-title":"E\ufb00ect of conbercept on corneal neovascularization in a rabbit model","volume":"38","author":"Du","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"R139-20260504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.18240\/ijo.2023.06.06","article-title":"Subconjunctival conbercept for the treatment of corneal neovascularization","volume":"16","author":"Sun","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"R140-20260504","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/bjo.60.6.464","article-title":"Corneal neovascularization treated with argon laser","volume":"60","author":"Cherry","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"R141-20260504","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00003226-200211000-00007","article-title":"Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization","volume":"21","author":"Gordon","year":"2002","journal-title":"Cornea"},{"key":"R142-20260504","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3928\/1542-8877-19981001-09","article-title":"Photodynamic therapy for corneal neovascularization","volume":"29","author":"Primbs","year":"1998","journal-title":"Ophthalmic Surg Lasers"},{"key":"R143-20260504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0974-9233.95246","article-title":"Photodynamic therapy with verteporfin for corneal neovascularization","volume":"19","author":"Al-Torbak","year":"2012","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R144-20260504","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajo.2007.05.028","article-title":"Photodynamic therapy with verteporfin for corneal neovascularization","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R145-20260504","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/ICO.0000000000000865","article-title":"Method for angiographically guided fine-needle diathermy in the treatment of corneal neovascularization","volume":"35","author":"Romano","year":"2016","journal-title":"Cornea"},{"key":"R146-20260504","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.xops.2022.100148","article-title":"Cotransplantation of limbal epithelial and stromal cells for ocular surface reconstruction","volume":"2","author":"Zhu","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"R147-20260504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1479-5876-12-58","article-title":"Results of a phase I\/II clinical trial: Standardized, non-xenogenic, cultivated limbal stem cell transplantation","volume":"12","author":"Zakaria","year":"2014","journal-title":"J Transl Med"},{"key":"R148-20260504","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamaophthalmol.2020.1120","article-title":"Outcomes of limbal stem cell transplant: A meta-analysis","volume":"138","author":"Le","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R149-20260504","doi-asserted-by":"crossref","first-page":"7325483","DOI":"10.1155\/2018\/7325483","article-title":"E\ufb00ect of collagen cross-linking on alkali burn-induced corneal neovascularization in rabbits","volume":"2018","author":"Xu","year":"2018","journal-title":"J Ophthalmol"},{"key":"R150-20260504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/02713683.2021.1971722","article-title":"Comparative analysis of matrix-regenerating agent and corneal cross-linking in an experimental alkali burn rabbit model","volume":"47","author":"Kesim","year":"2022","journal-title":"Curr Eye Res"},{"key":"R151-20260504","doi-asserted-by":"crossref","first-page":"112274","DOI":"10.1016\/j.msec.2021.112274","article-title":"Inhibiting corneal neovascularization by sustainably releasing anti-VEGF and anti-inflammation drugs from silica-thermogel nanohybrids","volume":"128","author":"Lyu","year":"2021","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"R152-20260504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2012.02.014","article-title":"Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea penetration, ocular distribution and e\ufb03cacy studies","volume":"81","author":"Di Tommaso","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"R153-20260504","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/pharmaceutics11120635","article-title":"Development of Kaempferol- loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice","volume":"11","author":"Chuang","year":"2019","journal-title":"Pharmaceutics"},{"key":"R154-20260504","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/IJN.S398769","article-title":"Functional peptide-loaded gelatin nanoparticles as eyedrops for cornea neovascularization treatment","volume":"18","author":"Chu","year":"2023","journal-title":"Int J Nanomedicine"},{"key":"R155-20260504","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.biopha.2018.08.092","article-title":"E\ufb00ect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy","volume":"107","author":"Zhang","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R156-20260504","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/ICO.0000000000000343","article-title":"Topically administered gold nanoparticles inhibit experimental corneal neovascularization in mice","volume":"34","author":"Cho","year":"2015","journal-title":"Cornea"},{"key":"R157-20260504","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1039\/C9TB01066A","article-title":"Cytocompatible cerium oxide-mediated antioxidative stress in inhibiting ocular inflammation-associated corneal neovascularization","volume":"7","author":"Zheng","year":"2019","journal-title":"J Mater Chem B"},{"key":"R158-20260504","doi-asserted-by":"crossref","first-page":"100163","DOI":"10.1016\/j.xops.2022.100163","article-title":"Topical nanoemulsion of a runt-related transcription factor 1 inhibitor for the treatment of pathologic ocular angiogenesis","volume":"2","author":"Delgado-Tirado","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"R159-20260504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","article-title":"Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation","volume":"125","author":"Soiberman","year":"2017","journal-title":"Biomaterials"},{"key":"R160-20260504","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/nn506599f","article-title":"Ocular drug delivery nanowafer with enhanced therapeutic e\ufb03cacy","volume":"9","author":"Yuan","year":"2015","journal-title":"ACS Nano"},{"key":"R161-20260504","first-page":"449","article-title":"Inhibition of vascularization in rabbit corneas by heparin: Cortisone pellets","volume":"27","author":"Nikolic","year":"1986","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R162-20260504","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ICO.0b013e3181605ff9","article-title":"Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline","volume":"27","author":"Aydin","year":"2008","journal-title":"Cornea"},{"key":"R163-20260504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1755-3768.1987.tb02600.x","article-title":"Cortisone, heparin and argon laser in the treatment of corneal neovascularization","volume":"182","author":"Tommila","year":"1987","journal-title":"Acta Ophthalmol Suppl (1985)"},{"key":"R164-20260504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICO.0b013e3181b1c82f","article-title":"The e\ufb00ect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits","volume":"29","author":"Kang","year":"2010","journal-title":"Cornea"},{"key":"R165-20260504","doi-asserted-by":"crossref","first-page":"122081","DOI":"10.1016\/j.ijpharm.2022.122081","article-title":"An injectable thermosensitive hydrogel for dual delivery of diclofenac and Avastin\u00ae to e\ufb00ectively suppress inflammatory corneal neovascularization","volume":"625","author":"Shi","year":"2022","journal-title":"Int J Pharm"},{"key":"R166-20260504","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.3390\/pharmaceutics15082059","article-title":"Sustained Inhibition of VEGF and TNF-\u03b1 achieves multi-ocular protection and prevents formation of blood vessels after severe ocular trauma","volume":"15","author":"Zhou","year":"2023","journal-title":"Pharmaceutics"},{"key":"R167-20260504","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"R168-20260504","first-page":"89","article-title":"Short-term regression of corneal neovascularization with combination therapy of argon green laser photocoagulation and subconjunctival bevacizumab","volume":"12","author":"Anand","year":"2019","journal-title":"Int Med Case Rep J"},{"key":"R169-20260504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.22336\/rjo.2021.58","article-title":"Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report","volume":"65","author":"Donato","year":"2021","journal-title":"Rom J Ophthalmol"},{"key":"R170-20260504","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/ICO.0000000000001016","article-title":"E\ufb00ects of combined photodynamic therapy and topical bevacizumab treatment on corneal neovascularization in rabbits","volume":"35","author":"Kim","year":"2016","journal-title":"Cornea"},{"key":"R171-20260504","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jfo.2015.06.006","article-title":"[Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and\/or photodynamic therapy]","volume":"38","author":"Hamdan","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"R172-20260504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10792-017-0786-x","article-title":"E\ufb00ectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens- Johnson syndrome","volume":"39","author":"Yoon","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R173-20260504","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/ICO.0b013e31823f8f7a","article-title":"Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: Fine-needle vessel coagulation combined with anti-VEGFs","volume":"31","author":"Koenig","year":"2012","journal-title":"Cornea"},{"key":"R174-20260504","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00417-021-05546-w","article-title":"Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab","volume":"260","author":"Mestanoglu","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R175-20260504","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/ICO.0000000000002502","article-title":"Descemet membrane endothelial keratoplasty in vascularized eyes: Outcome and e\ufb00ect on corneal neovascularization","volume":"40","author":"Hayashi","year":"2021","journal-title":"Cornea"},{"key":"R176-20260504","doi-asserted-by":"crossref","first-page":"e30842","DOI":"10.1371\/journal.pone.0030842","article-title":"Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn","volume":"7","author":"Yao","year":"2012","journal-title":"PLoS One"},{"key":"R177-20260504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymthe.2017.09.026","article-title":"Mesenchymal stromal cells inhibit Inflammatory lymphangiogenesis in the cornea by suppressing macrophage in a TSG-6-dependent manner","volume":"26","author":"Song","year":"2018","journal-title":"Mol Ther"},{"key":"R178-20260504","doi-asserted-by":"crossref","first-page":"e41858","DOI":"10.1371\/journal.pone.0041858","article-title":"Minocycline inhibits alkali burn-induced corneal neovascularization in mice","volume":"7","author":"Xiao","year":"2012","journal-title":"PLoS One"},{"key":"R179-20260504","first-page":"150","article-title":"Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK1\/2 and p38 pathways","volume":"4","author":"Zhong","year":"2011","journal-title":"Int J Ophthalmol"},{"key":"R180-20260504","doi-asserted-by":"crossref","first-page":"452685","DOI":"10.1155\/2014\/452685","article-title":"Inhibition of corneal neovascularization by topical and subconjunctival tigecycline","volume":"2014","author":"Goktas","year":"2014","journal-title":"J Ophthalmol"},{"issue":"3(Supplementary)","key":"R181-20260504","first-page":"1087","article-title":"Epigallocatechin gallate inhibits corneal neovascularization in ratalkaline burn model","volume":"31","author":"Li","year":"2018","journal-title":"Pak J Pharm Sci"},{"key":"R182-20260504","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000126081","article-title":"Inhibitory e\ufb00ect of curcumin on corneal neovascularization in vitro and in vivo","volume":"222","author":"Bian","year":"2008","journal-title":"Ophthalmologica"},{"key":"R183-20260504","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/02713680903528345","article-title":"The e\ufb00ect of curcumin on corneal neovascularization in rabbit eyes","volume":"35","author":"Kim","year":"2010","journal-title":"Curr Eye Res"},{"key":"R184-20260504","first-page":"154","article-title":"Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice","volume":"41","author":"Suzuki","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R185-20260504","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/ICO.0b013e318241433b","article-title":"Treatment of corneal neovascularization by topical application of ascorbic acid in the rabbit model","volume":"31","author":"Lee","year":"2012","journal-title":"Cornea"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3043_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:56Z","timestamp":1786650176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3043_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":185,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3043_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"2022-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}